WO2025024603A3 - Vaccins bactériens anticancéreux personnalisés - Google Patents

Vaccins bactériens anticancéreux personnalisés Download PDF

Info

Publication number
WO2025024603A3
WO2025024603A3 PCT/US2024/039426 US2024039426W WO2025024603A3 WO 2025024603 A3 WO2025024603 A3 WO 2025024603A3 US 2024039426 W US2024039426 W US 2024039426W WO 2025024603 A3 WO2025024603 A3 WO 2025024603A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer vaccines
personalized
bacterial cancer
bacteria
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/039426
Other languages
English (en)
Other versions
WO2025024603A2 (fr
Inventor
Yiannis N. KAZNESSIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elaine Tsiumas Kaznessis
Original Assignee
Elaine Tsiumas Kaznessis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elaine Tsiumas Kaznessis filed Critical Elaine Tsiumas Kaznessis
Publication of WO2025024603A2 publication Critical patent/WO2025024603A2/fr
Publication of WO2025024603A3 publication Critical patent/WO2025024603A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des vaccins bactériens anticancéreux personnalisés (PBCV) et des procédés associés, comprenant des procédés d'isolement de bactéries à partir du microbiome intestinal d'un patient, l'ingénierie génétique de bactéries sélectionnées, les voies d'administration et le dosage, la fabrication, l'approbation réglementaire, les tests de validation et l'évaluation de la réponse immunitaire et de l'efficacité thérapeutique.
PCT/US2024/039426 2023-07-25 2024-07-24 Vaccins bactériens anticancéreux personnalisés Pending WO2025024603A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363515419P 2023-07-25 2023-07-25
US63/515,419 2023-07-25

Publications (2)

Publication Number Publication Date
WO2025024603A2 WO2025024603A2 (fr) 2025-01-30
WO2025024603A3 true WO2025024603A3 (fr) 2025-04-03

Family

ID=94375479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/039426 Pending WO2025024603A2 (fr) 2023-07-25 2024-07-24 Vaccins bactériens anticancéreux personnalisés

Country Status (1)

Country Link
WO (1) WO2025024603A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207859A1 (fr) * 2015-06-24 2016-12-29 Advaxis, Inc. Dispositif de fabrication et procédé pour immunothérapie fondée sur un vecteur d'administration personnalisé
WO2019014398A1 (fr) * 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Souches bactériennes immunostimulatrices modifiées et utilisations
US20190307868A1 (en) * 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
US20200282037A1 (en) * 2017-06-16 2020-09-10 Nantbio, Inc. Bacterial vaccine
US11051871B2 (en) * 2013-06-03 2021-07-06 Pulse Biosciences, Inc. Methods and devices for stimulating an immune response using nanosecond pulsed electric fields
US20230226122A1 (en) * 2017-01-06 2023-07-20 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11051871B2 (en) * 2013-06-03 2021-07-06 Pulse Biosciences, Inc. Methods and devices for stimulating an immune response using nanosecond pulsed electric fields
WO2016207859A1 (fr) * 2015-06-24 2016-12-29 Advaxis, Inc. Dispositif de fabrication et procédé pour immunothérapie fondée sur un vecteur d'administration personnalisé
US20190307868A1 (en) * 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
US20230226122A1 (en) * 2017-01-06 2023-07-20 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
US20200282037A1 (en) * 2017-06-16 2020-09-10 Nantbio, Inc. Bacterial vaccine
WO2019014398A1 (fr) * 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Souches bactériennes immunostimulatrices modifiées et utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN Y. ERIN, ATABAKHSH KATAYOON, DIMAS ALEX, NAGASHIMA KAZUKI, FISCHBACH MICHAEL A.: "Eliciting a potent antitumor immune response by expressing tumor antigens in a skin commensal", BIORXIV, 17 February 2021 (2021-02-17), XP093300596, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.02.17.431662v1> DOI: 10.1101/2021.02.17.431662 *
JEONG JINUK, MUN SEYOUNG, OH YUNSEOK, CHO CHUN-SUNG, YUN KYEONGEUI, AHN YONGJU, CHUNG WON-HYONG, LIM MI YOUNG, LEE KYUNG EUN, HWAN: "A qRT-PCR Method Capable of Quantifying Specific Microorganisms Compared to NGS-Based Metagenome Profiling Data", MICROORGANISMS, MDPI AG, SWITZERLAND, vol. 10, no. 2, Switzerland, pages 324, XP093300597, ISSN: 2076-2607, DOI: 10.3390/microorganisms10020324 *

Also Published As

Publication number Publication date
WO2025024603A2 (fr) 2025-01-30

Similar Documents

Publication Publication Date Title
Hu et al. Characteristics, pathogenic mechanism, zoonotic potential, drug resistance, and prevention of avian pathogenic Escherichia coli (APEC)
Rosini et al. Vaccines against antimicrobial resistance
Mike et al. Siderophore vaccine conjugates protect against uropathogenic Escherichia coli urinary tract infection
Marks Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization
van Hal et al. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates
Prabhakara et al. Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus
Dockrell et al. Pneumococcal pneumonia: mechanisms of infection and resolution
Jenks et al. The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori
DK0950068T3 (da) Kollagen-bindende proteinsammensatninger og fremgangsmade til anvendelse
Bekeredjian-Ding Challenges for clinical development of vaccines for prevention of hospital-acquired bacterial infections
WO2006064451A3 (fr) Agents de contraste de ciblage ou agents therapeutiques de ciblage destines a une imagerie et a une therapie moleculaires
WO2002062378A3 (fr) Composition de vaccin
WO2007044406A3 (fr) Methodes permettant de stimuler une reponse immunitaire au moyen d&#39;un systeme de distribution d&#39;antigenes bacteriens
Grandi et al. Vaccination with a FAT1-derived B cell epitope combined with tumor-specific B and T cell epitopes elicits additive protection in cancer mouse models
Huy et al. Immunization with a combination of four recombinant Brucella abortus proteins Omp16, Omp19, Omp28, and L7/L12 induces T helper 1 immune response against virulent B. abortus 544 infection in BALB/c mice
MX2023009360A (es) Anticuerpos anti- variable delta 1 de tcr.
Fernández‐Rojas et al. Outer membrane vesicles of Pasteurella multocida contain virulence factors
Zhou et al. Biomimetic neutrophil nanotoxoids elicit potent immunity against Acinetobacter baumannii in multiple models of infection
US20160074480A1 (en) Innovative methods of treatmenting tuberculosis
AL et al. Isolation of Proteus mirabilis and Proteus vulgaris from different clinical sources and study of some virulence factors
WO2025024603A3 (fr) Vaccins bactériens anticancéreux personnalisés
Ebbers et al. Immunotherapy and vaccination against infectious diseases
Ramasamy et al. Principles of antidote pharmacology: an update on prophylaxis, post‐exposure treatment recommendations and research initiatives for biological agents
WO2022130015A3 (fr) Traitement de lymphocytes infiltrant les tumeurs
Amil et al. Comparison of therapeutic outcomes: two triple-therapy approaches for H. pylori eradication in gastric ulcer disease: two triple-therapy for H. pylori eradication

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24846462

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE